Royal Bank of Canada
BMY.RT

Royal Bank of Canada’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Royal Bank of Canada’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-202,142
Closed -$139K – 7963
2020
Q4 		$139K Sell
202,142
-37,094
-16% -$79K ﹤0.01% 5130
2020
Q3 		$539K Sell
239,236
-15,773
-6% -$45K ﹤0.01% 3787
2020
Q2 		$911K Sell
255,009
-59,007
-19% -$213K ﹤0.01% 3255
2020
Q1 		$1.19M Sell
314,016
-264,762
-46% -$872K ﹤0.01% 2893
2019
Q4 		$1.74M Buy
+578,778
New +$1.51M ﹤0.01% 2997

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Royal Bank of Canada's BMY.RT Position: Q1 2021 in Review

Royal Bank of Canada sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 202,142 shares — an estimated $139K sold.

Royal Bank of Canada first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.74M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Royal Bank of Canada reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 202,142 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $139K.
  • Royal Bank of Canada first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Royal Bank of Canada's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.74M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Royal Bank of Canada's 13F filing for Q1 2021, filed 17 May 2021.